Biogen Idec (BIIB) Affirms Receipt of FDA Approval for TECFIDERA as MS Treatment
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Biogen (BIIB) Target Raised to $215 at Jefferies after Tecfidera Approved with Favorable Label
March 28, 2013 9:12 AM EDTJefferies lifted its price target on Biogen (NASDAQ: BIIB) from $201 to $215 after the , the FDA approved Tecfidera (BG12) for multiple sclerosis.
"The label was better than we had expected, with a benign FDA requirement of annual white blood cell count monitoring, no... More
JMP Securities Starts Biogen (BIIB) at Market Outperform
March 28, 2013 7:13 AM EDTJMP Securities initiates coverage on Biogen (NASDAQ: BIIB) with a Market Outperform. PT $203.00.
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $182.68 yesterday, with a 52 week range of $124.23-$184.17.... More
What Next for Biogen (BIIB)? Anlaysts Weigh In
March 27, 2013 5:43 PM EDTOn Tuesday Biogen's (NASDAQ: BIIB) Tecfidera/BG12 was approved by the FDA. In addition to approval, the drug's label is considered "clean" .
Commenting on news, analyst Brian Abrahams of Wells Fargo said, "Overall the label reads relatively favorably, in our view, as expected . . . all eyes will now... More
XenoPort (XNPT) Pops Higher on Biogen (BIIB) Tecfidera Approval
March 27, 2013 3:54 PM EDTXenoPort, Inc. (NASDAQ: XNPT) shares are seeing some upside as the FDA approved Boigen's (Nasdaq: BIIB) Tecfidera (dimethyl fumarate) capsules to treat adults with relapsing forms of multiple sclerosis (MS).
Shares are up 0.8 percent.... More
Teva (TEVA) Hits Session Lows as Biogen (BIIB) MS Pill Gains Approval
March 27, 2013 3:53 PM EDTShares of Teva (NYSE: TEVA) declined late on Wednesday after news broke that the FDA approved Biogen's (Nasdaq: BIIB) Tecfidera (dimethyl fumarate) capsules to treat adults with relapsing forms of multiple sclerosis (MS).
Shares of Teva are lower by over 1 percent.... More
UPDATE: Biogen Idec (BIIB) wins FDA approval for MS pill
March 27, 2013 3:34 PM EDT(Updated - March 27, 2013 3:35 PM EDT)
Biogen Idec, Inc. (NASDAQ: BIIB) wins FDA approval for MS pill.
UPDATE - The FDA release is below:
The U.S. Food and Drug Administration today approved Tecfidera (dimethyl fumarate) capsules to treat adults with relapsing forms of multiple sclerosis (MS).
MS is a chronic, inflammatory, autoimmune disease of the central nervous system that disrupts communication between the brain and other parts of the body. It is among the most common causes of... More
